Abstract
Gene delivery/expression vectors have been used as fundamental technologies in gene therapy since the 1980s. These technologies are also being applied in regenerative medicine as tools to reprogram cell genomes to a pluripotent state and to other cell lineages. Rapid progress in these new research areas and expectations for their translation into clinical applications have facilitated the development of more sophisticated gene delivery/expression technologies. Since its isolation in 1953 in Japan, Sendai virus (SeV) has been widely used as a research tool in cell biology and in industry, but the application of SeV as a recombinant viral vector has been investigated only recently. Recombinant SeV vectors have various unique characteristics, such as low pathogenicity, powerful capacity for gene expression and a wide host range. In addition, the cytoplasmic gene expression mediated by this vector is advantageous for applications, in that chromosomal integration of exogenous genes can be undesirable. In this review, we introduce a brief historical background on the development of recombinant SeV vectors and describe their current applications in gene therapy. We also describe the application of SeV vectors in advanced nuclear reprogramming and introduce a defective and persistent SeV vector (SeVdp) optimized for such reprogramming.
Keywords: Sendai virus, gene therapy, nuclear reprogramming, induced pluripotent stem cells (iPSCs), regenerative medicine, viral vectors, gene delivery vectors, DNA–carrier
Current Gene Therapy
Title:Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine
Volume: 12 Issue: 5
Author(s): Mahito Nakanishi and Makoto Otsu
Affiliation:
Keywords: Sendai virus, gene therapy, nuclear reprogramming, induced pluripotent stem cells (iPSCs), regenerative medicine, viral vectors, gene delivery vectors, DNA–carrier
Abstract: Gene delivery/expression vectors have been used as fundamental technologies in gene therapy since the 1980s. These technologies are also being applied in regenerative medicine as tools to reprogram cell genomes to a pluripotent state and to other cell lineages. Rapid progress in these new research areas and expectations for their translation into clinical applications have facilitated the development of more sophisticated gene delivery/expression technologies. Since its isolation in 1953 in Japan, Sendai virus (SeV) has been widely used as a research tool in cell biology and in industry, but the application of SeV as a recombinant viral vector has been investigated only recently. Recombinant SeV vectors have various unique characteristics, such as low pathogenicity, powerful capacity for gene expression and a wide host range. In addition, the cytoplasmic gene expression mediated by this vector is advantageous for applications, in that chromosomal integration of exogenous genes can be undesirable. In this review, we introduce a brief historical background on the development of recombinant SeV vectors and describe their current applications in gene therapy. We also describe the application of SeV vectors in advanced nuclear reprogramming and introduce a defective and persistent SeV vector (SeVdp) optimized for such reprogramming.
Export Options
About this article
Cite this article as:
Nakanishi Mahito and Otsu Makoto, Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine, Current Gene Therapy 2012; 12 (5) . https://dx.doi.org/10.2174/156652312802762518
DOI https://dx.doi.org/10.2174/156652312802762518 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets Time Recall; Future Concept of Chronomodulating Chemotherapy for Cancer
Current Pharmaceutical Biotechnology Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response
Current Cancer Drug Targets Development of NGR-Based Anti-Cancer Agents for Targeted Therapeutics and Imaging
Anti-Cancer Agents in Medicinal Chemistry Effects of Specific Cyclooxygenase-2 Inhibitors on Carcinogenesis
Medicinal Chemistry Reviews - Online (Discontinued) Editorial: New Strategies and Applications for Drugs Targeting EGFR and c-Met
Current Drug Targets Regulatory Role of the α7nAChR in Cancer
Current Drug Targets Microglial Integrity is Maintained by Erythropoietin Through Integration of Akt and Its Substrates of lycogen Synthase Kinase-3β, β-Catenin, and Nuclear Factor-κB
Current Neurovascular Research New Generation of Liposomal Drugs for Cancer
Anti-Cancer Agents in Medicinal Chemistry Activity of Drug-loaded Tumor-Penetrating Microparticles In Peritoneal Pancreatic Tumors
Current Cancer Drug Targets To Seek Shelter from the Wnt in Osteoarthritis? Wnt-Signaling as a Target for Osteoarthritis Therapy
Current Drug Targets Multimodal HDAC Inhibitors with Improved Anticancer Activity
Current Cancer Drug Targets Reprogrammed Metabolism of Cancer Cells as a Potential Therapeutic Target
Current Pharmaceutical Design Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology Reversing Aberrant Methylation Patterns in Cancer
Current Medicinal Chemistry Isoniazid: Metabolic Aspects and Toxicological Correlates
Current Drug Metabolism Telomere Maintenance Mechanisms in Cancer: Clinical Implications
Current Pharmaceutical Design Electrochemically Driven Supramolecular Interaction of Quinones and Ferrocifens: An Example of Redox Activation of Bioactive Compounds
Current Topics in Medicinal Chemistry Progress in the Understanding of the Immune Microenvironment and Immunotherapy in Malignant Pleural Mesothelioma
Current Drug Targets Intraperitoneal Oncolytic and Tumor Vaccination Therapy with Replication-Competent Recombinant Virus: The Herpes Paradigm
Current Gene Therapy